Aradigm Corp., of Hayward, Calif., said results of a Phase II study showed insulin inhaled via its AERx system immediately before a meal achieved glucose control comparable to regular insulin injected 30 minutes before a meal. The study included 20 insulin-dependent adults with Type 1 diabetes.

Centocor Inc., of Malvern, Pa., and Eli Lilly and Co., of Indianapolis, formed a partnership to create a database that follows patients with acute coronary syndromes, from onset through outcome. The goal is to define optimal treatment strategies. It is called the Acute Coronary Syndromes Registry.

Introgen Therapeutics Inc., of Austin, Texas, said it earned a $6 million equity milestone payment from Rhone-Poulenc Rorer Pharmaceuticals Inc., of Collegeville, Pa., related to their collaboration on RPR/INGN 201 (adenoviral-p53), a gene therapy treatment for cancer. The companies completed three Phase II trials and are planning to go into Phase III. (See BioWorld Today, May 18, 1999, p. 1.)

Pangea Systems Inc., of Oakland, Calif., signed six licensing agreements for its bioinformatics software and data sets. Licensing GeneWorld software were Rigel Inc., of South San Francisco, and Ontogeny Inc., of Cambridge, Mass. Licensing clustering and alignment tools were EOS Technology Inc., of Santa Clara, Calif.; Axys Pharmaceuticals Inc., of South San Francisco; and an unnamed pharmaceutical company. Licensing the metabolic pathways data set was Genecore International Inc., of Rochester, N.Y.

Collateral Therapeutics, of San Diego, said a preclinical study published in Circulation found that the AC-6 gene may improve heart function in an animal model that closely resembles human congestive heart failure. The company expects to begin trial in humans of Corgenic, an AC-6 gene therapy treatment, early next year.